Synonyms: Acuphase® | cis(Z)-cloflupentixol | Cisordinol® | Clopixol® | NSC 64087 | NSC169185
zuclopenthixol is an approved drug
Compound class:
Synthetic organic
Comment: Zuclopenthixol is a thioxanthene class typical antipsychotic. Chemically it is the cis-isomer of clopenthixol. The CAS registry number (53772-83-1) submitted with the WHO INN record for zuclopenthixol maps to PubChem CID 5311507.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: zuclopenthixol |
|
No information available. |
Summary of Clinical Use |
Used to treat schizophrenia and acute mania. There is no information regarding approval for clinical use of this drug on the US FDA or European Medicines Agency (EMA) websites. Individual national approval agencies may have granted marketing authorisation. See Drugs.com for a list of countries where this drug may be in use. In the UK three salt formulations of zuclopenthixol are approved; acetate (PubChem CID 6436640, injectable form), decanoate (PubChem CID 6450333, injectable form) and dihydrochloride (PubChem CID 6433208), tablet form). |
Mechanism Of Action and Pharmacodynamic Effects |
Zuclopenthixol is an antagonist of the dopamine D1 and D2 receptor subtypes. Drug treatment induces sedation and improves psychotic symptoms. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) |